Drugstore of the future -- new drugs from an old source

November 10, 2010

Toronto, ON (Nov. 10 2010) -- Supported by thousands of years of use, a new wave of polymolecular botanical drugs (PBDs), backed by strong biomedical research and clinical trials, are growing in acceptance as a viable new drug category for the treatment and prevention of a wide spectrum of diseases from cancer to obesity.

Leading researchers in drug development from the National Cancer Institute, Wake Forest University, the University of California, the Scripps Centre for Integrative Medicine, King's College in London UK, and many Canadian Universities will be among the twenty panellists at a Toronto forum on November 15th. Speakers will highlight recent discoveries, discuss current and future research, and chart regulatory landscapes for the promising field of polymolecular drug development. Treatment areas include diabetes, cholesterol management, and cancer.

Research findings will be presented illustrating the advances in the development of polymolecular drugs and their growing recognition as potential mainstream therapies to not only treat illness, but to prevent it. Since polymolecular drugs are composed of multiple components, they often produce biological and/or clinical efficacy through multiple mechanisms of action rather than through a single pathway, as conventional drugs do. An added advantage of this new class of drugs is the synergy between their components, which allows for lower concentrations of each individual ingredient with no reduction in efficacy. As a result they are, as a category, safer and more tolerable than conventional drugs.

Discussion will also focus on recent successes in standardization, which overcome the greatest challenge of botanical medicine and allow for assurances of consistency, safety, and efficacy.

The list of speakers at the forum will include:Academic and clinical researchers, business development professionals and government agencies involved in the drug development field have been invited to attend and learn about this emerging field of health and therapeutics, and to network with other professionals in the field.
-end-
Learn more about the November 15th meeting in Toronto by calling 416-644-2287 or visiting the MaRS Discovery District website at www.marsdd.com/events. A webinar of the event will be posted after the event.

CV Technologies Inc.

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.